Finally, in vivo experiments demonstrated that the simultaneous overexpression of TRMT10A and inhibition of tRF-22 significantly reduced glioma size and VM numbers more effectively than either TRMT10A overexpression or tRF-22 inhibition alone. Here, TRMT10A is linked to central nervous system cancer.